Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

Recruiting now

Conditions studied: Primary Biliary Cirrhosis

In brief

Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.

Key facts

Study ID

NCT04514965

Run by

University of Aarhus

People needed

100

Starts

2020-10-01

Expected to finish

2026-09-01

Last updated by the study team

2022-08-12

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PBC patient offered bezafibrate treatment

You may not qualify if…

• patient age under 18
• life expectancy less than 6 months
• known cancer
• planned liver transplantation within 6 months
• other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)

Where it is running

• Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark — Aarhus N, Central Jutland, Denmark (enrolling)
• Department of Medicine, Gastrounit Medical division — Hvidovre, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.